Drug Profile
Research programme: PCSK9 mRNA inhibitors - Roche
Alternative Names: LNA PCSK-9; PCSK9 inhibitorLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antisense oligonucleotides
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in Denmark (Parenteral)
- 05 Jan 2017 CiVi Biopharma and Roche agree to co-promote and co-develop PCSK9 mRNA inhibitors for Hypercholesterolaemia in Denmark
- 05 Jan 2017 Roche plans a phase I trial for Hypercholesterolaemia